CJC1295/Ipamorelin – 10 mg

CJC-1295 and Ipamorelin are two structurally distinct research peptides investigated through complementary pathways within the growth-hormone signaling axis. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a synthetic peptide studied for its activity at the ghrelin receptor, GHS-R1a. The 10 mg presentation is intended for qualified research environments conducting controlled investigations into peptide pharmacology, receptor signaling, growth-hormone-axis biology, and related cellular pathways.

Key Features

10 mg research peptide combination CJC-1295 / Modified GRF research compound Ipamorelin research peptide Two distinct peptides associated with growth-hormone-axis research Relevant to GHRH receptor and GHS-R1a receptor studies Suitable for controlled laboratory research Intended for in-vitro and preclinical research workflows Appropriate for research programs requiring analytical and batch-level documentation Research Focus CJC-1295 and Ipamorelin are studied through different receptor pathways. CJC-1295 is associated with GHRH-receptor signaling, while Ipamorelin is investigated as a GHS-R1a receptor agonist. Their distinct molecular targets make the combination relevant to research examining interconnected growth-hormone signaling pathways.

Important Notice

This product is supplied strictly for research and laboratory use. It is not intended for human or veterinary use, self-administration, consumption, diagnosis, treatment, or prevention of disease. This research material should be handled only by appropriately qualified personnel in accordance with applicable laboratory protocols and regulations.